Loading…
Genprex, Inc. is projected to decline to $4.35 by 2027, a -8% move from its current price of $4.75. GNPX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.40 | $4.75 | $5.13 | +0.02% |
| Aug 6 | $4.27 | $4.75 | $5.29 | +0.04% |
| Aug 7 | $4.17 | $4.75 | $5.42 | +0.07% |
| Aug 8 | $4.08 | $4.75 | $5.53 | +0.09% |
| Aug 9 | $4.01 | $4.76 | $5.64 | +0.11% |
| Aug 10 | $3.95 | $4.76 | $5.73 | +0.13% |
| Aug 11 | $3.89 | $4.76 | $5.82 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.89 | $4.76 | $5.82 | +0.15% |
| Week 2 | $3.59 | $4.76 | $6.33 | +0.31% |
| Week 3 | $3.37 | $4.77 | $6.76 | +0.47% |
| Week 4 | $3.20 | $4.78 | $7.14 | +0.62% |
| Week 5 | $3.05 | $4.79 | $7.50 | +0.78% |
| Week 6 | $2.93 | $4.79 | $7.84 | +0.93% |
| Week 7 | $2.82 | $4.80 | $8.17 | +1.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. Its oncology program uses its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
Genprex was incorporated in 2009 and is based in Austin, Texas. Its lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. The company also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies, and its diabetes gene therapy comprises a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
Genprex, Inc. (GNPX) is a health care stock with a current price of $6.06 and a market cap of $3.06M, ranking 5099 by market capitalization. The stock sits in the healthcare sector as a clinical-stage biotech focused on gene therapies for cancer and diabetes.
Forecasts show near-term price activity around the current level in 2026, with a 2026 range of $6.06 to $8.16 and an average near $6.06, implying little upside in the first year. Longer term, the model projects gradual gains toward the 2030s and meaningful upside by the 2040s and 2050, with 2050 values around $14.24 on average and as high as $32.76.
A major floor 90.8% below — a decisive break under it would weaken the trend.
Support has flipped 26.1% overhead — reclaiming it would be bullish.
The nearest ceiling, 187.6% above — a clean break opens room to run.
A major ceiling 187.6% above — clearing it would confirm fresh momentum.
Key GNPX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GNPX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.99 | Sell | $6.67 | Sell |
| MA 10 | $7.39 | Sell | $6.49 | Sell |
| MA 20 | $4.70 | Buy | $5.26 | Sell |
| MA 50 | $2.26 | Buy | $3.28 | Buy |
| MA 100 | $1.80 | Buy | $2.70 | Buy |
| MA 200 | $2.99 | Buy | $6.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.25 | Neutral |
| Stoch RSI (14) | 41.48 | Neutral |
| CCI (20) | 26.01 | Neutral |
| Williams %R (14) | -30.45 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | 1119.96 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 69.55 | Neutral |
| TRIX (15) | 11.28 | Buy |
| Awesome (5,34) | 4.01 | Buy |
| Ultimate (7,14,28) | 39.80 | Neutral |
| Momentum (10) | -1.68 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 6.33 | Sell |
| ADX (14) | 43.86 | Buy |
| ATR (14) | 0.54 | Info |
The 30-day technical picture is neutral. The RSI(14) is 30, and the stock trades with a neutral sentiment.
The 50-day simple moving average is $12.31, while the 200-day simple moving average sits at $57.39. Support is noted at $6.06 and resistance at $13.66. The 30-day price range spans from a low of $3.62 to a high of $10.15, suggesting limited near-term upside within the current trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.75 | $4.75 | $6.33 | 0% | Neutral | |
| $3.17 | $4.35 | $6.45 | -8% | Neutral | |
| $2.81 | $4.10 | $6.49 | -14% | Neutral | |
| $2.37 | $3.65 | $6.07 | -23% | Bearish | |
| $3.14 | $5.06 | $8.76 | +7% | Neutral | |
| $3.89 | $6.57 | $11.77 | +38% | Bullish | |
| $3.26 | $5.73 | $10.60 | +21% | Bullish | |
| $3.19 | $5.84 | $11.10 | +23% | Bullish | |
| $2.98 | $5.69 | $11.08 | +20% | Neutral | |
| $2.39 | $4.73 | $9.43 | 0% | Neutral | |
| $3.44 | $7.65 | $16.78 | +61% | Bullish | |
| $4.94 | $10.99 | $25.27 | +131% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.75 | $4.75 | $5.50 | +0.00% |
| September 2026 | $3.77 | $4.58 | $5.81 | -3.56% |
| October 2026 | $3.93 | $4.85 | $6.27 | +5.80% |
| November 2026 | $3.80 | $4.74 | $6.23 | -2.26% |
| December 2026 | $3.77 | $4.75 | $6.33 | +0.23% |
Click any year to see its month-by-month GNPX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GNPX could reach as high as $6.33, with a base case around $4.75 and support toward $4.75 — roughly 0% from $4.75. Price action looks broadly range-bound.
Expect GNPX to range from $3.17 to $6.45 through 2027. The $4.35 average target implies a -8% move from current prices. That is -8% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The GNPX price prediction for 2028 points to an average of $4.10 (low $2.81, high $6.49) — a potential decline of -14% on today's $4.75. Price action looks broadly range-bound.
In 2029, GNPX is projected to trade between $2.37 and $6.07, averaging $3.65 — a potential decline of -23% from today's $4.75. That is -11% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
Genprex, Inc.'s 2030 outlook centres on $5.06, within a $3.14 to $8.76 range. That is up +39% on the projected 2029 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2031, GNPX could reach as high as $11.77, with a base case around $6.57 and support toward $3.89 — roughly +38% from $4.75. Buyers look set to stay in control over this stretch.
Expect GNPX to range from $3.26 to $10.60 through 2032. The $5.73 average target implies a +21% move from current prices. That is -13% versus the projected 2031 average. Momentum favours further upside here.
The GNPX price prediction for 2033 points to an average of $5.84 (low $3.19, high $11.10) — a potential gain of +23% on today's $4.75. Buyers look set to stay in control over this stretch.
In 2034, GNPX is projected to trade between $2.98 and $11.08, averaging $5.69 — a potential gain of +20% from today's $4.75. That is -3% versus the projected 2033 average. Price action looks broadly range-bound.
Genprex, Inc.'s 2035 outlook centres on $4.73, within a $2.39 to $9.43 range. That is -17% versus the projected 2034 average. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, GNPX could reach as high as $16.78, with a base case around $7.65 and support toward $3.44 — roughly +61% from $4.75. Momentum favours further upside here.
Expect GNPX to range from $4.94 to $25.27 through 2050. The $10.99 average target implies a +131% move from current prices. That is up +44% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GNPX today (≈ 210.526316 GNPX) could be worth
$2,313.32
+$1,313.32 (+131%) by 2050 · US Dollar
Based on the average projected GNPX price of $10.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GNPXwould be worth at today's price.
$1,000 invested in GNPX on Jul 31, 2025 (≈ 86.580085 GNPX) would be worth
$411.26
-$588.74 (-58.9%) today · 0.41× · US Dollar
Based on a GNPX entry price of $11.55 vs. today's $4.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.81 | $608.19 | -39.2% |
| 1 month ago | $0.534 | $8,895.13 | +789.5% |
| 3 months ago | $0.918 | $5,174.29 | +417.4% |
| 6 months ago | $2.49 | $1,907.63 | +90.8% |
| 1 year ago | $11.55 | $411.26 | -58.9% |
| All time (5.0y) ago | $5,980 | $0.79 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GNPX forecast.
Our base-case forecast reaches $9.50 around 2050.
Implied market cap at $9.50: $4.8M
The multi-year forecast shows a muted start in 2026, with min and average prices both at $6.06 and a max of $8.16 and a 0% ROI. The following years tilt bearish through 2029, with 2027 min $4.06, avg $5.57, max $8.27 (ROI -8.1%), 2028 min $3.52, avg $5.15, max $8.15 (ROI -15.1%), and 2029 min $3.07, avg $4.72, max $7.85 (ROI -22.1%).
In 2030 the forecast turns modestly positive: min $4.04, avg $6.51, max $11.28 (ROI 7.5%). The next years show better momentum, with 2031 min $4.93, avg $8.31, max $14.90 (ROI 37.1%), 2032 min $4.17, avg $7.34, max $13.57 (ROI 21.1%), and 2033 min $4.07, avg $7.46, max $14.18 (ROI 23.1%). 2034 sits near flat with min $3.79, avg $7.22, max $14.07 (ROI 19.1%), and 2035 moves lower again with min $3.07, avg $6.08, max $12.12 (ROI 0.3%).
The path improves into 2040, where the forecast shows min $4.34, avg $9.65, max $21.17 (ROI 59.2%), and then accelerates toward 2050 with min $6.41, avg $14.24, max $32.76 (ROI 135.1%), accompanied by a bullish sentiment.
Overall, these figures illustrate a long-run upside potential with significant dispersion year to year. These are estimates and not guarantees, reflecting market-driven projections rather than promises.
Tap a question to reveal the answer.
The 2030 forecast shows min $4.04, avg $6.51, max $11.28 with ROI 7.5% and sentiment Neutral.
The forecast indicates mixed signals: 2026-2029 are bearish, followed by modest gains in 2030-2033 and stronger upside from 2031 onward, culminating in notable long-term upside by 2040 and 2050 (ROI 7.5% in 2030 and 135.1% by 2050).
Yes. The 2030 forecast lists a maximum of $11.28.
Current price is $6.06 and market cap is $3.06M.
For 2050, the forecast shows min $6.41, avg $14.24, max $32.76 with ROI 135.1% and sentiment Bullish.
Genprex, Inc. Community Discussion
0Share your Genprex, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.